Revolve Wealth Partners LLC Has $625,000 Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Revolve Wealth Partners LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 5.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,733 shares of the company’s stock after acquiring an additional 227 shares during the period. Revolve Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $625,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Burkett Financial Services LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $28,000. Bare Financial Services Inc bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $28,000. Rakuten Securities Inc. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $30,000. Finally, RIA Advisory Group LLC bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at $30,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MRK shares. Berenberg Bank raised their price target on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research note on Monday, March 11th. Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Argus raised shares of Merck & Co., Inc. to a “strong-buy” rating in a research note on Wednesday, June 5th. Finally, TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Merck & Co., Inc. Stock Down 1.3 %

Shares of NYSE MRK opened at $129.79 on Friday. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $134.63. The stock has a market capitalization of $328.73 billion, a P/E ratio of 144.21, a P/E/G ratio of 2.54 and a beta of 0.39. The company has a 50-day moving average price of $129.27 and a 200-day moving average price of $123.96. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. During the same period in the previous year, the company earned $1.40 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. On average, equities research analysts forecast that Merck & Co., Inc. will post 8.62 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.37%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 342.22%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.